Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
-9.74% $2.77
America/New_York / 27 mar 2024 @ 14:29
FUNDAMENTALS | |
---|---|
MarketCap: | 3.57 mill |
EPS: | -13.35 |
P/E: | -0.210 |
Earnings Date: | Apr 15, 2024 |
SharesOutstanding: | 1.288 mill |
Avg Daily Volume: | 0.0101 mill |
RATING 2024-03-27 |
---|
B- |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Neutral | |
Return On Equity: | Strong Buy | |
Return On Asset: | Sell | |
DE: | Strong Sell | |
P/E: | Neutral | |
Price To Book: | Strong Sell |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -0.210 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.04x |
Company: PE -0.210 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
N/A |
N/A |
Expected Trading Range (DAY) |
---|
$ 2.36 - 3.18 ( +/- 14.73%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-18 | Catlin Michael | Buy | 18 000 | Restricted Stock Award |
2024-03-18 | Misajon Pamela | Buy | 18 000 | Restricted Stock Award |
2024-03-18 | Nagel Michael | Buy | 18 000 | Restricted Stock Award |
2023-10-05 | Bersani Pietro | Buy | 65 600 | Restricted Stock Units |
2023-10-05 | Misajon Pamela | Buy | 7 500 | Restricted Stock Units |
INSIDER POWER |
---|
100.00 |
Last 47 transactions |
Buy: 2 001 102 | Sell: 1 131 551 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 |
Volume Signals | |
---|---|
Price | $2.77 (-9.74% ) |
Volume | 0.0015 mill |
Avg. Vol. | 0.0101 mill |
% of Avg. Vol | 15.26 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
Kiromic BioPharma, Inc., an artificial intelligence driven allogeneic cell therapy company, engages in developing the multi-indication allogeneic T cell therapies that exploits the natural potency of the Gamma Delta T cell to target solid tumors. The company develops ALEXIS-ISO-1, an allogenic gamma delta CAR-T cell therapy product candidate targeting Isomesothelin; and ALEXIS-PRO-1, an allogeneic gamma delta chimeric T cell therapy product candidate targeting PD-L1. It has license agreements with CGA 369 Intellectual Holdings, Inc. and Longwood University, as well as a research and development collaboration agreement with Molipharma, S.R.L. The company also has strategic alliance agreement with Leon Office (H.K.) Ltd. The company was formerly known as Kiromic, Inc. and changed its name to Kiromic BioPharma, Inc. in December 2019. Kiromic BioPharma, Inc. was founded in 2006 and is headquartered in Houston, Texas.